Global Contrast and Imaging Agents in Interventional X-ray Market Industry Trends Forecast to 2026

TABLE OF CONTENTS

1 INTRODUCTION 19

• 1.1 OBJECTIVES OF THE STUDY 19
• 1.2 MARKET DEFINITION 19
• 1.3 OVERVIEW OF GLOBAL CONTRAST AND IMAGING AGENTS IN INTERVENTIONAL X-RAY MARKET 19
• 1.4 CURRENCY AND PRICING 21
• 1.5 LIMITATION 21
• 1.6 MARKETS COVERED 21

2 MARKET SEGMENTATION 24

• 2.1 MARKETS COVERED 24
• 2.2 GEOGRAPHIC SCOPE 25
• 2.3 YEARS CONSIDERED FOR THE STUDY 26
• 2.4 CURRENCY AND PRICING 26
• 2.5 RESEARCH METHODOLOGY 27
• 2.6 PRIMARY INTERVIEWS WITH KEY OPINION LEADERS 30
• 2.7 DBMR MARKET CHALLENGE MATRIX 31
• 2.8 MARKET APPLICATION COVERAGE GRID 32
• 2.9 DBMR VENDOR SHARE ANALYSIS 33
• 2.10 SECONDARY SOURCES 34
• 2.11 ASSUMPTIONS 34

3 MARKET OVERVIEW 35

• 3.1 DRIVERS 37
  • 3.1.1 RISING NUMBER OF CHRONIC DISEASES 37
  • 3.1.2 RISING AGING POPULATION 38
  • 3.1.3 GROWING NUMBER OF DIAGNOSTIC CENTERS 39
  • 3.1.4 INCREASE IN THE RESEARCH AND DEVELOPMENTAL ACTIVITIES OF CONTRAST AGENTS 40
• 3.2 RESTRAINT 42
  • 3.2.1 SIDE EFFECTS ASSOCIATED WITH CONTRAST AGENTS 42
• 3.3 OPPORTUNITIES 42
  • 3.3.1 RISING HEALTHCARE EXPENDITURE 42
  • 3.3.2 INCREASE IN NUMBER OF PUBLIC AND PRIVATE HOSPITALS 45
• 3.4 CHALLENGE 46
  • 3.4.1 LACK OF AWARENESS REGARDING THE PROPER DOSAGE OF CONTRAST AGENT 46

4 EXECUTIVE SUMMARY 47

5 PREMIUM INSIGHTS 50

6 KEY PRIMARY INSIGHTS 53

7 GLOBAL CONTRAST AND IMAGING AGENTS IN INTERVENTIONAL X-RAY MARKET, BY AGENT TYPE 54

• 7.1 OVERVIEW 55
• 7.2 IODINATED CONTRAST MEDIA 56
• 7.3 BARIUM-BASED CONTRAST MEDIA 57
• 7.4 MICROBUBBLE CONTRAST MEDIA 57
• 7.5 GOLD NANOPARTICLE CONTRAST AGENTS 58
• 7.6 OTHERS 58

8 GLOBAL CONTRAST AND IMAGING AGENTS IN INTERVENTIONAL X-RAY MARKET, BY APPLICATION 59

• 8.1 OVERVIEW 60
• 8.2 CARDIOLOGY 62
  • 8.2.1 PERCUTANEOUS CORONARY INTERVENTION 63
  • 8.2.2 STRUCTURAL HEART DISEASE 63
  • 8.2.3 CONGENITAL HEART DISEASE 63
  • 8.2.4 ELECTROPHYSIOLOGY 63
• 8.3 GASTROENTEROLOGY 63
• 8.4 NEUROLOGY 64
• 8.5 ONCOLOGY 64
• 8.6 UROLOGY 65
• 8.7 GENERAL SURGERY 65

9 GLOBAL CONTRAST AND IMAGING AGENTS IN INTERVENTIONAL X-RAY MARKET, BY END USER 66

• 9.1 OVERVIEW 67
• 9.2 IMAGING CENTERS 68
• 9.3 HOSPITAL 69
• 9.4 CLINICS 69
• 9.5 DIAGNOSTIC CENTER 70
• 9.6 AMBULATORY SURGICAL CENTERS 70
• 9.7 PRIVATE PRACTICES 71

10 GLOBAL CONTRAST AND IMAGING AGENTS IN INTERVENTIONAL X-RAY MARKET, BY GEOGRAPHY 72

• 10.1 OVERVIEW 73
• 10.2 NORTH AMERICA 78
  • 10.2.1 U.S. 84
  • 10.2.2 CANADA 86
  • 10.2.3 MEXICO 88
• 10.3 EUROPE 90
  • 10.3.1 GERMANY 96
  • 10.3.2 U.K. 98
  • 10.3.3 FRANCE 100
  • 10.3.4 ITALY 102
  • 10.3.5 SPAIN 104
  • 10.3.6 SWITZERLAND 106
  • 10.3.7 NETHERLANDS 108
  • 10.3.8 RUSSIA 110
  • 10.3.9 BELGIUM 112
  • 10.3.10 TURKEY 114
  • 10.3.11 REST OF EUROPE 116
• 10.4 ASIA PACIFIC 117
  • 10.4.1 CHINA 123
  • 10.4.2 JAPAN 125
  • 10.4.3 INDIA 127
  • 10.4.4 AUSTRALIA 129
  • 10.4.5 SOUTH KOREA 131
  • 10.4.6 SINGAPORE 133
  • 10.4.7 MALAYSIA 135
  • 10.4.8 INDONESIA 137
  • 10.4.9 THAILAND 139
  • 10.4.10 PHILIPPINES 141
  • 10.4.11 REST OF ASIA PACIFIC 143
• 10.5 SOUTH AMERICA 144
  • 10.5.1 BRAZIL 150
  • 10.5.2 REST OF SOUTH AMERICA 152
• 10.6 MIDDLE EAST & AFRICA 153
  • 10.6.1 SOUTH AFRICA 159
  • 10.6.2 REST OF MIDDLE EAST & AFRICA 161

11 GLOBAL CONTRAST AND IMAGING AGENTS IN INTERVENTIONAL X-RAY MARKET, COMPANY LANDSCAPE 162

• 11.1 COMPANY SHARE ANALYSIS: GLOBAL 162
• 11.2 COMPANY SHARE ANALYSIS: NORTH AMERICA 163
• 11.3 COMPANY SHARE ANALYSIS: EUROPE 164
• 11.4 COMPANY SHARE ANALYSIS: ASIA PACIFIC 165

12 COMPANY PROFILES 166

• 12.1 BRACCO 166
  • 12.1.1 COMPANY SNAPSHOT 166
  • 12.1.2 GEOGRAPHICAL PRESENCE 166
  • 12.1.3 COMPANY SHARE ANALYSIS 167
  • 12.1.4 PRODUCT PORTFOLIO 167
  • 12.1.5 RECENT DEVELOPMENTS 168
• 12.2 GENERAL ELECTRIC COMPANY 169
  • 12.2.1 COMPANY SNAPSHOT 169
  • 12.2.2 REVENEUE ANALYSIS 169
  • 12.2.3 COMPANY SHARE ANALYSIS 170
  • 12.2.4 PRODUCT PORTFOLIO 170
  • 12.2.5 RECENT DEVELOPMENTS 170
• 12.3 GUERBET 171
  • 12.3.1 COMPANY SNAPSHOT 171
  • 12.3.2 REVENEUE ANALYSIS 171
  • 12.3.3 COMPANY SHARE ANALYSIS 172
  • 12.3.4 PRODUCT PORTFOLIO 172
  • 12.3.5 RECENT DEVELOPMENTS 173
• 12.4 FUJIFILM VISUALSONICS INC. 173
  • 12.4.1 COMPANY SNAPSHOT 173
  • 12.4.2 GEOGRAPHICAL PRESENCE 174
  • 12.4.3 PRODUCT PORTFOLIO 175
  • 12.4.4 RECENT DEVELOPMENT 175
• 12.5 IMAX 176
  • 12.5.1 COMPANY SNAPSHOT 176
  • 12.5.2 GEOGRAPHICAL PRESENCE 176
  • 12.5.3 PRODUCT PORTFOLIO 177
  • 12.5.4 RECENT DEVELOPMENT 177
• 12.6 J.B. CHEMICALS & PHARMACEUTICALS LTD. 178
  • 12.6.1 COMPANY SNAPSHOT 178
  • 12.6.2 REVENUE ANALYSIS 178
  • 12.6.3 PRODUCT PORTFOLIO 179
  • 12.6.4 RECENT DEVELOPMENT 179
• 12.7 JODAS EXPOIM 180
  • 12.7.1 COMPANY SNAPSHOT 180
  • 12.7.2 GEOGRAPHICAL PRESENCE 180
  • 12.7.3 PRODUCT PORTFOLIO 181
  • 12.7.4 RECENT DEVELOPMENTS 181
• 12.8 LANTHEUS MEDICAL IMAGING, INC. 182
  • 12.8.1 COMPANY SNAPSHOT 182
  • 12.8.2 REVENUE ANALYSIS 182
  • 12.8.3 PRODUCT PORTFOLIO 183
  • 12.8.4 RECENT DEVELOPMENTS 183
• 12.9 NANO THERAPEUTICS PVT. LTD. 184
  • 12.9.1 COMPANY SNAPSHOT 184
  • 12.9.2 GEOGRAPHICAL PRESENCE 184
  • 12.9.3 PRODUCT PORTFOLIO 185
  • 12.9.4 RECENT DEVELOPMENT 185
• 12.10 NOVALEK PHARMACEUTICALS PVT. LTD. 186
  • 12.10.1 COMPANY SNAPSHOT 186
  • 12.10.2 GEOGRAPHICAL PRESENCE 186
  • 12.10.3 PRODUCT PORTFOLIO 187
  • 12.10.4 RECENT DEVELOPMENT 187
• 12.11 TAEJOON PHARM 188
  • 12.11.1 COMPANY SNAPSHOT 188
  • 12.11.2 GEOGRAPHICAL PRESENCE 188
  • 12.11.3 PRODUCT PORTFOLIO 189
  • 12.11.4 RECENT DEVELOPMENT 189
• 12.12 UNIJULES LIFE SCIENCES LTD. 190
  • 12.12.1 COMPANY SNAPSHOT 190
  • 12.12.2 PRODUCT PORTFOLIO 190
  • 12.12.3 RECENT DEVELOPMENT 190

13 QUESTIONNAIRE 191

14 RELATED REPORTS 194